首頁 > 市場調查報告書 > 製藥

藥物開發

市場調查報告書

商品編碼

1624411

藥物發現服務市場：依流程、類型、藥物類型、治療領域和地區劃分，2024-2031 年

Drug Discovery Services Market By Process, Type, Drug Type, Therapeutic Area, & Region for 2024-2031

出版日期: 2024年10月03日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024-2031 年藥物發現服務市場評估

隨著對創新治療和生物技術突破的需求不斷增長，製藥公司越來越多地轉向外包，以降低與研發相關的成本並加快新藥的上市時間，這推動了藥物發現服務市場的發展。據 Verified Market Research 分析師稱，藥物發現服務市場預計到 2024 年將突破約 128.2 億美元，並在預測期內達到 287.1 億美元的估值。

基因組學和蛋白質組學的快速發展以及藥物研發支出的增加正在推動藥物發現服務市場。因此，2024年至2031年市場將以11.70%的複合年增長率成長。

藥物發現服務市場定義/概述

藥物發現服務是由專業合約研究組織 (CRO) 進行的外包研究和開發業務，以識別和開發新化合物。這些服務包括廣泛的活動，包括標靶識別、分析開發、高通量篩選、先導化合物優化和臨床試驗。

此外，藥物發現服務具有廣泛的應用，包括加速新藥開發、提供先進技術和專業知識、簡化新藥研究方法以及顯著降低新藥上市所需的成本和時間。這些服務對於希望簡化研發工作、降低風險並專注於核心優勢，同時利用 CRO 的專業技能和資源的製藥公司至關重要。

增加研發投入將如何推動市場成長？

在大量投資的支持下，製藥業正在加大對研發的投入，這是主要的驅動力。這些投資旨在開發創新療法，以滿足未滿足的醫療需求，特別是在腫瘤學和神經學領域。隨著全球慢性病發病率的上升需要持續創新，製藥公司正在將部分藥物發現服務外包給專業提供者，以提高效率和創新。

高通量篩選、生物資訊學和基因組學方面的技術進步正在推動藥物發現服務市場。這些技術能夠以比現有方法更便宜和更快的速度快速篩選大型化學庫。此外，人工智慧和機器學習在預測藥物行為、優化藥物設計和識別可行的治療候選藥物、減少藥物開發階段相關的時間和成本方面變得越來越重要。

此外，大型製藥和生物技術公司越來越多地透過策略聯盟和外包來利用 CRO 的專業知識和先進技術。外包藥物發現使公司能夠專注於核心競爭力，有效控製成本並加快新療法的上市時間。這種方法對於沒有內部資源進行大規模藥物開發活動的中小型生技公司尤其重要。

影響藥物發現服務市場的主要課題有哪些？

藥物發現是一項昂貴且高風險的事業，新療法的開發耗資數十億美元，而且往往需要 10 年以上的時間。失敗率很高，尤其是在早期階段，阻礙了投資並危及專案的財務可行性。這些費用和風險對於不具備大型製藥公司財力的中小企業來說尤其沉重。

此外，在競爭激烈的藥物發現領域，保護智慧財產權 (IP) 至關重要。然而，管理智慧財產權很困難，尤其是當涉及許多合作夥伴時，就像外包藥物發現研究計畫的情況一樣。智慧財產權所有權和專利權可能會發生衝突，導致法律問題並阻礙新藥的開發和商業化。

The growing trend of outsourcing by pharmaceutical companies to decrease costs associated with research and development and speed up time-to-market for new pharmaceuticals, along with the growing need for innovative therapies and biotechnology breakthroughs, are driving the drug discovery services market. According to the analyst from Verified Market Research, the drug discovery services market is estimated to reach a valuation of USD 28.71 Billion over the forecast subjugating around USD 12.82 Billion valued in 2024.

The rapid developments in genomics and proteomics, together with increased spending in pharmaceutical R&D, are driving the drug discovery services market, as is the requirement for specialized knowledge in drug development procedures. It enables the market to grow at aCAGR of 11.70% from 2024 to 2031.

Drug Discovery Services Market: Definition/ Overview

Drug discovery services are the outsourced research and development activities performed by specialist contract research organizations (CROs) to identify and develop new pharmaceutical compounds. These services encompass a wide range of operations, including target identification, assay development, high-throughput screening, hit-to-lead optimization, and clinical testing.

Furthermore, drug discovery services have a wide range of applications, including accelerating the development of new medications, providing access to advanced technologies and expertise, improving the efficiency of drug research processes, and significantly lowering the costs and time required to bring new drugs to market. These services are critical for pharmaceutical companies looking to streamline their R&D efforts, reduce risks, and focus on core strengths while harnessing the specialized skills and resources of CROs.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How will Increase in R&D Investments Drive the Growth of the Market?

The pharmaceutical industry's rising commitment to R&D, backed by significant investments, is a primary driver. These investments are intended to develop innovative therapeutics to treat unmet medical needs, particularly in oncology and neurology. The increased global frequency of chronic diseases needs ongoing innovation, prompting pharmaceutical companies to outsource portions of their drug discovery services to specialist service providers, therefore increasing efficiency and innovation.

Technological improvements in high-throughput screening, bioinformatics, and genomics are driving the drug discovery services market. These technologies enable the rapid screening of large chemical libraries at cheaper prices and faster rates than existing approaches. Furthermore, AI and machine learning are becoming increasingly important in predicting drug behavior, optimizing drug design, and identifying viable therapeutic candidates, thus decreasing the time and cost associated with drug development phases.

Furthermore, big pharma and biotech businesses are increasingly leveraging CROs' specialized knowledge and advanced technology through strategic cooperation and outsourcing. Outsourcing drug discovery enables businesses to focus on core capabilities, effectively control costs, and reduce time to market for new treatments. This method is especially important for smaller biotech companies that lack the internal resources to perform large-scale drug development activities.

What are the Primary Challenges Impacting the Drug Discovery Services Market?

Drug discovery is an expensive and high-risk enterprise, with the development of a new treatment frequently costing billions of dollars and taking more than a decade. The failure rate is particularly high in the early phases, discouraging investment and putting the project's financial viability at risk. These expenses and hazards are especially onerous for smaller businesses that lack the financial resources of larger pharmaceutical enterprises.

Furthermore, protecting intellectual property (IP) is critical in the competitive world of drug discovery. However, managing IP rights is difficult, especially when numerous partners are involved, as is common in outsourced drug research projects. Conflicts over intellectual property ownership and patent rights may arise, resulting in legal issues and impeding the development and commercialization of novel drugs.

Category-Wise Acumens

What are the Factors Supporting the Dominance of Small Molecules in the Market?

According to VMR analysis, the small molecules segment is estimated to hold the largest market share in the drug type segment during the forecast period. Small-molecule drugs are typically less expensive to manufacture and scale than biologics. They can be generated in huge quantities using chemical procedures, making them more easily produced and distributed. Because of their low cost, small molecules are especially appealing to pharmaceutical businesses seeking to optimize their return on investment.

Small molecules have a lengthy history in the pharmaceutical industry, thus there are well-established regulatory channels for their development and approval. This familiarity streamlines medication discovery, decreases regulatory approval uncertainty, and shortens time-to-market, making them a popular choice among pharmaceutical corporations.

Furthermore, small molecules easily permeate cells and influence a wide range of biological targets, making them useful for treating a variety of disorders, both chronic and acute. This broad applicability bolsters ongoing research and development efforts, allowing them to maintain their lead in the drug discovery services market.

How does Oncology Propel the Growth of the Drug Discovery Services Market?

The oncology segment is estimated to dominate the drug discovery services market during the forecast period. The global rise in cancer incidence is a significant motivator for the emphasis on oncology in drug discovery. As cancer remains the biggest cause of death worldwide, there is a strong desire for novel and more effective cancer treatments. This need encourages pharmaceutical companies and research organizations to engage extensively in oncology research, resulting in the growth of this market segment.

The evolution of precision medicine, particularly in oncology, has had a substantial impact on medication discovery. Advances in genetic sequencing and molecular diagnostics enable more precise and individualized cancer treatments. This emphasis on unique patient profiles and tumor genetics has moved drug research efforts toward more personalized solutions, improving the efficacy and success rates of oncology drugs.

Furthermore, oncology has one of the most extensive drug development pipelines in all therapeutic fields. The continual discovery of new targets and routes for cancer treatment drives continued research and development. Also, the high likelihood of market approval and commercial success for oncology medications encourages investment in this sector, reinforcing its market share domination in drug discovery services.

Country/Region-wise Acumens

How Does the Rising Biopharmaceutical Sector Drive the Market in the Asia Pacific?

According to VMR analyst, North America is estimated to dominate the drug discovery services market during the forecast period. North America has a highly developed biopharmaceutical sector, with the United States dominating in terms of innovation, drug development, and market approvals. This region is home to several of the world's leading pharmaceutical and biotech companies, which continue to invest in medication discovery and development. This climate promotes robust R&D activity, attracting large investments and partnerships to propel the market ahead.

Furthermore, the presence of advanced research infrastructures, such as world-class universities, research institutes, and cutting-edge laboratories, facilitates large-scale drug development initiatives. North America receives major government and private financing for therapeutic research in fields such as oncology, neurology, and cardiovascular disease, which is crucial to the continued discovery of new drugs.

What are the Primary Factors Driving the Drug Discovery Services in Asia Pacific?

The Asia Pacific region is estimated to exhibit the highest growth within the drug discovery services market during the forecast period. Many countries in the Asia-Pacific region are experiencing rapid economic growth and higher healthcare spending. As these economies flourish, more resources are directed toward healthcare, including investments in innovative medical treatments and research centers. This economic development promotes the growth of the pharmaceutical and biotechnology sectors, increasing demand for drug discovery services.

Furthermore, the Asia Pacific region is experiencing an increase in the prevalence of chronic diseases such as diabetes, cardiovascular disease, and cancer, which is being driven by changing lifestyles and an aging population. This increase in disease prevalence is driving up the need for innovative and effective treatment medications, strengthening the regional drug discovery services market.

Competitive Landscape

The competitive landscape of the drug discovery services market is characterized by a wide range of vendors providing specialized services at various stages of the drug development pipeline. Furthermore, there is a growing trend toward customization and tailored service models to meet the individual needs of clients, which adds to the competitiveness.

Some of the prominent players operating in the drug discovery services market include:

Abbott Laboratories, Inc.

Advinus Therapeutics

Agilent Technologies Ubiquigent

Albany Molecular Research, Inc.

AstraZeneca PLC

Aurigene

Bayer AG

Charles River Laboratories International

ChemBridge Corporation

Covance

Latest Developments

In February 2023, Charles River Laboratories signed a multi-program agreement with Pioneering Medicines, a Flagship Pioneering (US) initiative, to use its Logica Al platform for small-molecule drug discovery.

In February 2023, Evotec SE and Related Sciences signed a multi-target drug discovery deal. The two firms sought to choose, research, and develop precisely targeted medications to address unmet patient needs.

In January 2023, Charles River Laboratories purchased SAMDI Tech, Inc., which provides label-free HTS solutions for drug discovery research. The acquisition provided CRL with experience in label-free HTS MS platforms and resulted in a broad library of drug discovery options.

1 INTRODUCTION OF DRUG DISCOVERY SERVICES MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 DRUG DISCOVERY SERVICES MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 DRUG DISCOVERY SERVICES MARKET, BY PROCESS

5.1 Overview
5.2 Target Selection
5.3 Target Validation
5.4 Hit-To-Lead Identification
5.5 Lead Optimization
5.6 Candidate Validation

6 DRUG DISCOVERY SERVICES MARKET, BY TYPE

6.1 Overview
6.2 Medicinal Chemistry Services
6.3 Biology Services
6.4 Drug Metabolism and Pharmacokinetics (DMPK)
6.5 Market, by Drug Type
6.6 Small- molecule Drugs
6.7 Biologic Drugs

7 GLOBAL DRUG DISCOVERY MARKET, BY DRUG TYPE

7.1 Overview
7.2 Small Molecule Drugs
7.3 Biologic Drugs

8 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA

8.1 Overview
8.2 Oncology
8.3 Neurology
8.4 Infectious and Immune System Diseases
8.5 Digestive System Diseases
8.6 Cardiovascular Diseases
8.7 Other Therapeutic Areas

9 DRUG DISCOVERY SERVICES MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East

10 DRUG DISCOVERY SERVICES MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11 COMPANY PROFILES

11.1 Abbott Laboratories Inc.
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Advinus Therapeutics
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Agilent Technologies Ubiquigent
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Albany Molecular Research Inc.
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 AstraZeneca PLC
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 Aurigene
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 Bayer AG
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Charles River Laboratories International
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 ChemBridge Corporation
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 Covance
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments